Understanding the Impact of FDA Modernization Act 2.0 on Drug Development Blog Post
Learn how the FDA Modernization Act 2.0 will change the drug development landscape by allowing alternative methods to animal testing.
How QSP brings insights and accelerates bispecific antibody drug development Blog Post
Wednesday, August 9th 2023 More than 50 bispecific antibodies are in oncology clinical development with a large diversity in formats, directed at a range of immune and tumor targets. Bispecifics…
Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome Blog Post
Madin–Darby canine kidney (MDCK) cells are widely used to study epithelial cell functionality. Their low endogenous drug transporter protein levels make them an amenable system to investigate transepithelial permeation and…
DIDB® – The Drug Interaction Database, is now part of Certara Blog Post
PRINCETON, N.J.— June 20, 2023 — Certara, Inc. (Nasdaq: CERT), today announced it has acquired Drug Interaction Solutions from the University of Washington. This transaction brings a world-renowned team of…
Model-Informed Approaches and Innovative Clinical Trial Design for Adeno-Associated Viral Vector-Based Gene Therapy Product Development: A White Paper Blog Post
Abstract The promise of viral vector-based gene therapy (GT) as a transformative paradigm for treating severely debilitating and life-threatening diseases is slowly coming to fruition with the recent approval of...
Certara Appoints new Chief Marketing Officer, Sheila Rocchio Blog Post
Princeton, N.J., June 13, 2023 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Shelia Rocchio to the position of Chief Marketing Officer. In this…
What’s New for SEND 2023 Blog Post
This webinar will focus on several changes to the CDISC SEND standard that became active in March of 2023 and what these changes mean for dataset creators and users. Changes…
Certara Launches Version 8.4 of Phoenix™ Biosimulation Software for Drug Development Blog Post
Latest updates demonstrate commitment to customers and market leadership of Phoenix Platform PRINCETON, N.J.— June 12, 2023. Certara®, the global leader in biosimulation, today announced the launch of version 8.4…
Certara enhances CODEX Clinical Outcome Analytics Platform with AI Blog Post
Trial design and execution now accelerated by deep learning and data fabric capabilities. PRINCETON, NJ June 8 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, is integrating new…
Leveraging Pharmacokinetic Modeling & Scientific Communications Expertise Advances Sarcoidosis Drug Program Blog Post
Certara’s support, from dose optimization to medical writing, helps pharmaceutical companies advance their research, make informed decisions & publish their research.
